ARTICLE | Politics, Policy & Law

Largely aspirational, Biden’s COVID-19 strategy hints at chance for long-term impact on drug development

The question is whether plans for expansion of data, diagnostics and health equity will come to fruition

January 30, 2021 3:18 AM UTC

The Biden administration’s strategy for COVID-19 and long-term pandemic preparedness is in large part a plan for a plan, but it contains kernels of concepts that if fully developed could transform how drug companies conduct clinical trials, use real-world data, and reach into underserved communities. 

Among the 200 pages of President Joe Biden’s National Strategy for the COVID-19 Response and Pandemic Preparedness are three areas beyond vaccine development and distribution that could present meaningful long-term change for biopharmas and patients if taken to the limit: testing and diagnostics, data collection and integration, and health equity...